Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency

A Corrigendum to this article was published on 24 July 2014

Abstract

5-Fluorouracil (5-FU) is rapidly degraded by dihyropyrimidine dehydrogenase (DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following treatment with 5-FU or capecitabine. Different tests based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants have been studied for screening for DPD deficiency, but none of these are implemented broadly into clinical practice. We give an overview of the tests that can be used to detect DPD deficiency and discuss the advantages and disadvantages of these tests.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Diasio RB, Harris BE . Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215–237.

    Article  CAS  PubMed  Google Scholar 

  2. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899–2902.

    CAS  PubMed  Google Scholar 

  3. Harris BE, Song R, Soong SJ, Diasio RB . Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201.

    CAS  PubMed  Google Scholar 

  4. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994; 12: 2248–2253.

    Article  CAS  PubMed  Google Scholar 

  5. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 2002; 101: 253–258.

    Article  CAS  PubMed  Google Scholar 

  6. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K et al. Toxic death-case after capecitabine+oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol 2006; 58: 272–275.

    Article  CAS  PubMed  Google Scholar 

  7. Maring JG, van Kuilenburg AB, Haasjes J, Piersma H, Groen HJ, Uges DR et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 2002; 86: 1028–1033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. van Kuilenburg AB, Hausler P, Schalhorn A, Tanck MW, Proost JH, Terborg C et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012; 51: 163–174.

    Article  CAS  PubMed  Google Scholar 

  9. Mercier C, Ciccolini J . Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 2007; 28: 597–598.

    Article  CAS  PubMed  Google Scholar 

  10. Yang CG, Ciccolini J, Blesius A, Dahan L, Bagarry-Liegey D, Brunet C et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemother Pharmacol 2011; 67: 49–56.

    Article  CAS  PubMed  Google Scholar 

  11. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149–1153.

    CAS  PubMed  Google Scholar 

  12. Lu Z, Zhang R, Carpenter JT, Diasio RB . Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res 1998; 4: 325–329.

    CAS  PubMed  Google Scholar 

  13. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007; 249: 271–282.

    Article  CAS  PubMed  Google Scholar 

  14. van Kuilenburg AB, van Lenthe H, Van Gennip AH . Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1211–1214.

    Article  CAS  PubMed  Google Scholar 

  15. Naguib FN, el Kouni MH, Cha S . Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 1985; 45: 5405–5412.

    CAS  PubMed  Google Scholar 

  16. Lu Z, Zhang R, Diasio RB . Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433–5438.

    CAS  PubMed  Google Scholar 

  17. van Kuilenburg AB, van LH, Zoetekouw L, Kulik W . HPLC-electrospray tandem mass spectrometry for rapid determination of dihydropyrimidine dehydrogenase activity. Clin Chem 2007; 53: 528–530.

    Article  CAS  PubMed  Google Scholar 

  18. van Kuilenburg AB, van LH, Tromp A, Veltman PC, Van Gennip AH . Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 2000; 46: 9–17.

    CAS  PubMed  Google Scholar 

  19. Johnson MR, Yan J, Shao L, Albin N, Diasio RB . Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. J Chromatogr B Biomed Sci Appl 1997; 696: 183–191.

    Article  CAS  PubMed  Google Scholar 

  20. Dobashi K, Ohe E, Yamaguchi K, Takeshita S, Ayabe T, Miyazaki M et al. Severe 5-fluorouracil-induced toxicity due to increased dihydropyrimidine dehydrogenase activity: report of a patient survival and urinary pyrimidine and dihydropyrimidine levels. Int J Clin Oncol 1999; 4: 241–243.

    Article  Google Scholar 

  21. Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P et al. A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 482–488.

    Article  CAS  PubMed  Google Scholar 

  22. Liem LK, Choong LH, Woo KT . Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese, Indian and Malay in Singapore by using semi-automated HPLC-radioassay. Clin Biochem 2002; 35: 181–187.

    Article  CAS  PubMed  Google Scholar 

  23. Di PA, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301–1306.

    Article  Google Scholar 

  24. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB . Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin Cancer Res 2004; 10: 2652–2658.

    Article  CAS  PubMed  Google Scholar 

  25. Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR et al. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clin Cancer Res 2006; 12: 549–555.

    Article  CAS  PubMed  Google Scholar 

  26. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB . Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006; 12: 5491–5495.

    Article  CAS  PubMed  Google Scholar 

  27. van Staveren MC, Theeuwes-Oonk B, Guchelaar HJ, van Kuilenburg AB, Maring JG . Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 2011; 68: 1611–1617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28: 678–685.

    Article  CAS  PubMed  Google Scholar 

  29. Bi D, Anderson LW, Shapiro J, Shapiro A, Grem JL, Takimoto CH . Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B Biomed Sci Appl 2000; 738: 249–258.

    Article  CAS  PubMed  Google Scholar 

  30. Ben FR, Gross E, Ben AS, Hassine H, Saguem S . The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil. Pathol Biol (Paris) 2009; 57: 470–476.

    Article  Google Scholar 

  31. Ciccolini J, Mercier C, Blachon MF, Favre R, Durand A, Lacarelle B . A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity. J Clin Pharm Ther 2004; 29: 307–315.

    Article  CAS  PubMed  Google Scholar 

  32. Zhou ZW, Wang GQ, Wan dS, Lu ZH, Chen YB, Li S et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007; 53: 127–131.

    Article  CAS  PubMed  Google Scholar 

  33. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, Delva R, Lortholary A, Genevieve F et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105.

    Article  CAS  PubMed  Google Scholar 

  34. Garg MB, Sevester JC, Sakoff JA, Ackland SP . Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 774: 223–230.

    Article  CAS  PubMed  Google Scholar 

  35. Sumi S, Kidouchi K, Ohba S, Wada Y . Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 672: 233–239.

    Article  CAS  PubMed  Google Scholar 

  36. Remaud G, Boisdron-Celle M, Hameline C, Morel A, Gamelin E . An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 823: 98–107.

    Article  CAS  PubMed  Google Scholar 

  37. Kristensen MH, Pedersen P, Mejer J . The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 2010; 38: 1313–1323.

    Article  CAS  PubMed  Google Scholar 

  38. Jiang H, Lu J, Ji J . Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004; 141: 616–623.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Di PA, Danesi R, Ciofi L, Vannozzi F, Bocci G, Lastella M et al. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit 2005; 27: 362–368.

    Article  Google Scholar 

  40. Deporte-Fety R, Picot M, Amiand M, Moreau A, Campion L, Lanoe D et al. High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 2001; 762: 203–209.

    Article  CAS  PubMed  Google Scholar 

  41. Remaud G, Boisdron-Celle M, Morel A, Gamelin A . Sensitive MS/MS-liquid chromatography assay for simultaneous determination of tegafur, 5-fluorouracil and 5-fluorodihydrouracil in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 824: 153–160.

    Article  CAS  PubMed  Google Scholar 

  42. Beumer JH, Boisdron-Celle M, Clarke W, Courtney JB, Egorin MJ, Gamelin E et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit 2009; 31: 688–694.

    Article  CAS  PubMed  Google Scholar 

  43. Bocci G, Barbara C, Vannozzi F, Di PA, Melosi A, Barsanti G et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006; 80: 384–395.

    Article  CAS  PubMed  Google Scholar 

  44. Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000; 6: 3032–3037.

    CAS  PubMed  Google Scholar 

  45. Di PA, Danesi R, Vannozzi F, Falcone A, Mini E, Cionini L et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther 2002; 72: 627–637.

    Article  Google Scholar 

  46. van Kuilenburg AB, Maring JG, Schalhorn A, Terborg C, Schmalenberg H, Behnke D et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1 G>A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 2008; 27: 692–698.

    Article  CAS  PubMed  Google Scholar 

  47. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB . A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal Biochem 2002; 306: 63–73.

    Article  CAS  PubMed  Google Scholar 

  48. Fischer J, Schwab M, Eichelbaum M, Zanger UM . Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 2003; 7: 97–105.

    Article  CAS  PubMed  Google Scholar 

  49. Gross E, Ullrich T, Seck K, Mueller V, de Wit WM, von Schilling SC et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498.

    Article  PubMed  Google Scholar 

  50. van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364: 157–163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Weidensee S, Goettig P, Bertone M, Haas D, Magdolen V, Kiechle M et al. A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding. Clin Biochem 2011; 44: 722–724.

    Article  CAS  PubMed  Google Scholar 

  52. Ahluwalia R, Freimuth R, McLeod HL, Marsh S . Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem 2003; 49: 1661–1664.

    Article  CAS  PubMed  Google Scholar 

  53. Amstutz U, Farese S, Aebi S, Largiader CR . Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10: 931–944.

    Article  CAS  PubMed  Google Scholar 

  54. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895–2904.

    Article  CAS  PubMed  Google Scholar 

  55. Nauck M, Gierens H, Marz W, Wieland H . Rapid detection of a common dihydropyrimidine dehydrogenase mutation associated with 5-fluorouracil toxicity and congenital thymine uraciluria using fluorogenic hybridization probes. Clin Biochem 2001; 34: 103–105.

    Article  CAS  PubMed  Google Scholar 

  56. Salgueiro N, Veiga I, Fragoso M, Sousa O, Costa N, Pellon ML et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med 2004; 6: 102–107.

    Article  CAS  PubMed  Google Scholar 

  57. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, van LH, De Abreu RA et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705–4712.

    CAS  PubMed  Google Scholar 

  58. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455–3468.

    Article  CAS  PubMed  Google Scholar 

  59. van Kuilenburg AB, Meijer J, Mul AN, Meinsma R, Schmid V, Dobritzsch D et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet 2010; 128: 529–538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, van LH et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1–9.

    Article  CAS  PubMed  Google Scholar 

  61. Giorgio E, Caroti C, Mattioli F, Uliana V, Parodi MI, D'Amico M et al. Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol 2011; 68: 1355–1361.

    Article  CAS  PubMed  Google Scholar 

  62. Magne N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 2007; 64: 237–240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Okamoto Y, Ueta A, Sumi S, Ito T, Okubo Y, Jose Y et al. SSCP screening of the dihydropyrimidine dehydrogenase gene polymorphisms of the Japanese population using a semi-automated electrophoresis unit. Biochem Genet 2007; 45: 713–724.

    Article  CAS  PubMed  Google Scholar 

  64. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB . Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11: 8699–8705.

    Article  CAS  PubMed  Google Scholar 

  65. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M et al. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 2004; 10: 7100–7107.

    Article  CAS  PubMed  Google Scholar 

  66. Amstutz U, Farese S, Aebi S, Largiader CR . Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy. J Exp Clin Cancer Res 2008; 27: 54.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues A, Dias PC et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010; 10: 470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Raida M, Schwabe W, Hausler P, van Kuilenburg AB, Van Gennip AH, Behnke D et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832–2839.

    CAS  PubMed  Google Scholar 

  69. Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res 2005; 11: 5886–5892.

    Article  CAS  PubMed  Google Scholar 

  70. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB . Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000; 278: 175–184.

    Article  CAS  PubMed  Google Scholar 

  71. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH . High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12: 555–558.

    Article  CAS  PubMed  Google Scholar 

  72. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131–2138.

    Article  CAS  PubMed  Google Scholar 

  73. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77: 441–451.

    Article  CAS  Google Scholar 

  74. van Kuilenburg AB, van LH, Blom MJ, Mul EP, Van Gennip AH . Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999; 79: 620–626.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M C van Staveren.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Staveren, M., Jan Guchelaar, H., van Kuilenburg, A. et al. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J 13, 389–395 (2013). https://doi.org/10.1038/tpj.2013.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2013.25

Keywords

This article is cited by

Search

Quick links